Institute for Molecular Medicine Finland
Institute for Molecular Medicine Finland (FIMM) is an international research institute in Helsinki focusing on human genomics and personalized medicine. FIMM integrates molecular medicine research, Technology Centre and Biobanking Infrastructures “under one roof” and thereby promotes translational research and adoption of personalized medicine in health care.
FIMM was founded in 2006, a few years after the launch of an initiative to establish an international Molecular Medicine Research Centre in Finland. FIMM is hosted by the University of Helsinki. The Hospital District of Helsinki and Uusimaa (HUS) and the National Institute for Health and Welfare (THL) were also involved in the establishment of the institute and we continue to maintain a close partnership with them. In the beginning of 2017 we joined the university’s new life science research center, Helsinki Institute of Life Science (HiLIFE), as a scientifically and financially independent operational unit.
FIMM researchers are involved in several Grand Challenge projects, such as the impact of genome information from the Finnish population in personalized health and medical interventions, development of individualized cancer medicine, and novel diagnostics via imaging of tissue and cells. The disease areas of interest for the 18 research groups cover cancer, cardiovascular diseases, diabetes, addictions, neurological and neuropsychiatric diseases and immunological diseases.
FIMM Technology Centre and Biobanking Infrastructures provide research services for local, national and international customers, including collaborations with companies. The infrastructures operated by FIMM are networked with European ESFRI infrastructures BBMRI, EATRIS, ELIXIR and EU-Openscreen.
FIMM is characterised first and foremost by our partnership with the flagship of European biosciences research, the European Molecular Biology Laboratory (EMBL). As part of the Nordic EMBL Partnership for Molecular Medicine, composed of the European Molecular Biology Laboratory (EMBL) and the centers for molecular medicine in Norway, Sweden and Denmark, we follow the EMBL operational model and principles. This means aiming at scientific excellence and establishing mechanisms for independent, regular scientific evaluation of research activities, scientific integrity and good scientific practice, as well as commitment to international recruitment and significant levels of staff turnover.
Another important international network for us is EU-LIFE (European Life Sciences Institutes for Excellence), comprising thirteen top biomedical research institutes from Europe. FIMM has been a member of this network since 2013.